CTMX stock forecast, quote, news & analysis

Key Takeaways

• CytomX Therapeutics shares fell roughly 14% over the last 30 days, sliding from about $2.69 (September 28) to $2.31 (October 27) as post-offering dilution overhang and speculative-biotech selling pressure persisted.
• The move extends a longer downtrend: the stock is down about 28% over the last quarter and roughly 46% year to date, within a 52-week range of $2.20 to $8.21.
• No single company-specific negative catalyst triggered the decline; it instead reflects a Q2 2026 revenue miss, heavy short interest near 23% of float, and rising Treasury yields pressuring risk assets.
• CytomX's lead candidate, Varseta-M (CX-2051), continues to show encouraging activity in late-line colorectal cancer, with confirmed response rates of 20%–32%, and a registrational study is targeted for the first half of 2027.
• The company held $346.7 million in cash, cash equivalents and investments as of March 31, 2026, supporting a projected runway into the second half of 2028.
• Wall Street consensus remains constructive despite the decline, with average price targets near $12 versus a share price around $2.31.
• For more detail on this ticker, explore CytomX's Price Targets, Earnings, and Forecast pages.
• Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.

CytomX Therapeutics (CTMX) Company Overview and Market Position

CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a clinical-stage, oncology-focused biopharmaceutical company headquartered in South San Francisco, California. The company's core asset is its PROBODY® platform, which uses molecular masking to create conditionally activated biologics that remain inactive in healthy tissue and become active primarily within the tumor microenvironment. This design is intended to widen the therapeutic window for potent drug classes, including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines.

CytomX's lead program, Varseta-M (varsetatug masetecan; CX-2051), is a masked, EpCAM-directed topoisomerase-1 inhibitor ADC being developed for metastatic colorectal cancer. Its second clinical program, CX-801, is a masked interferon alpha-2b cytokine in development for metastatic melanoma. The company has established collaborations with major oncology partners including Amgen (AMGN), Bristol Myers Squibb (BMY), Regeneron (REGN), and Moderna (MRNA). Investors follow the stock closely for clinical data readouts, regulatory progress, and the platform's validation through partnerships.

CytomX Therapeutics (CTMX) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CTMX declined approximately 14%, falling from a closing price of $2.69 on September 28, 2026, to $2.31 on October 27, 2026. The move was characterized by persistent selling pressure rather than a sharp single-day event, with the shares setting a new 52-week intraday low of $2.18 on October 26.

The 30-day decline is part of a steeper quarterly downtrend. Three months earlier, on July 28, 2026, the stock closed near $3.22, translating to a drop of roughly 28% over the last quarter. The shares have traded in a broad range over the past year—between $2.20 and $8.21—reflecting both the early-2026 rally around positive Varseta-M data and the subsequent fade as dilution and revenue headwinds weighed on sentiment.

What Drove CTMX Stock Price in the Last 30 Days

The recent decline was not tied to a single company-specific announcement. Instead, several factors compounded to push the shares lower. A second-quarter revenue miss continued to reverberate: the company reported $1.42 million in revenue against expectations near $12.4 million, as collaboration revenue from completed Bristol Myers Squibb and Astellas programs wound down. Heavy short interest—about 40.8 million shares, or roughly 23% of the public float as of late September—added to downward pressure.

Rising Treasury yields and broader risk-off sentiment toward speculative small-cap biotechnology also contributed, alongside routine analyst adjustments. Some firms lowered targets (J.P. Morgan moved from $12 to $11; Guggenheim from $15 to $14), while others maintained constructive views—Cantor Fitzgerald reiterated an Overweight rating with a $12 target on October 13 and Piper Sandler reiterated $12 in late September. The net effect was a steady grind lower rather than a sharp catalyst-driven break.

What Drove CTMX Stock Performance Over the Last Quarter

The quarterly trend reflects the unwind of an earlier rally. CTMX surged to a 52-week high of $8.21 in the first quarter of 2026 after Phase 1 data showed Varseta-M achieving a 32% confirmed response rate at the 10 mg/kg dose in late-line colorectal cancer. That enthusiasm was tempered in March by a $250 million public offering priced at $5.30 per share—a discount of about 21% to the prior close—which significantly increased the share count and pressured the stock.

Since then, the shares have drifted lower as collaboration revenue declined, operating expenses rose to support Varseta-M manufacturing, and investors awaited the next data catalysts. The company's strengthened balance sheet and extended cash runway into the second half of 2028 have provided some support, but near-term clinical and regulatory milestones remain the primary drivers of sentiment.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. While Tickeron offers hundreds of AI trading bots that trade thousands of tickers, only the top-performing and most relevant bots appear in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches ranging from short-term momentum to longer-horizon trend following. The page serves as a practical starting point for traders seeking data-driven, algorithm-based signals across a broad universe of securities. Investors interested in systematic approaches can review the Trending AI Robots to evaluate how automated strategies are navigating current market conditions.

CTMX Stock Forecast Drivers: What Investors Should Watch Next

Several near-term catalysts could shape CTMX's trajectory. The company has guided to a Phase 1 safety and efficacy update for Varseta-M in the second half of 2026, including progression-free survival from dose-optimization cohorts and an initial overall-survival look, which is intended to inform FDA alignment on a registrational trial design. A pivotal late-line colorectal cancer study is targeted to begin in the first half of 2027, and initial data for CX-801 in combination with pembrolizumab (Keytruda) in advanced melanoma is expected around year-end 2026.

Investors should also monitor FDA interactions on Varseta-M's registrational path, expansion into additional EpCAM-expressing tumor types, and the company's cash position relative to its development plans. Macroeconomic factors—including interest rates and risk appetite for pre-revenue biotech—and the stock's elevated short interest remain important sentiment considerations. As with any clinical-stage biotechnology company, binary clinical outcomes and regulatory decisions carry meaningful risk, and this information should not be interpreted as investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations